# Different Doses of Olaparib Given With Radium-223 in Men With Advanced Prostate Cancer With Bone Metastasis

> **NCT03317392** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 132 (actual)

## Conditions studied

- Castration-Resistant Prostate Carcinoma
- Metastatic Prostate Adenocarcinoma
- Stage IVB Prostate Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biopsy Procedure
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **OTHER:** Laboratory Biomarker Analysis
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Olaparib
- **OTHER:** Quality-of-Life Assessment
- **RADIATION:** Radium Ra 223 Dichloride

## Key facts

- **NCT ID:** NCT03317392
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-02-04
- **Primary completion:** 2025-03-31
- **Final completion:** 2027-02-16
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03317392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03317392, "Different Doses of Olaparib Given With Radium-223 in Men With Advanced Prostate Cancer With Bone Metastasis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03317392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*